Circulating levels of granulocyte macrophage colony-stimulating factor in patients with the systemic inflammatory response syndrome

Objectives. Granulocyte-macrophage colony stimulating factor (GM-CSF) is a key regulator cytokine that modulates the proliferation and maturation of polymorphonuclear and mononuclear progenitors. This study was designed to investigate and clarify the role of GM-CSF in 52 critically ill patients with...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infection 2003-11, Vol.47 (4), p.296-299
Main Authors: Torre, Donato, Tambini, Roberto, Manfredi, Mariangela, Mangani, Valerio, Livi, Paola, Maldifassi, Viviana, Chiaranda, Maurizio, Campi, Paolo, Speranza, Filippo
Format: Article
Language:English
Subjects:
Analysis of Variance
Biological and medical sciences
Colony stimulating factor
Enzyme-Linked Immunosorbent Assay
Female
Fundamental and applied biological sciences. Psychology
General aspects
Granulocyte-macrophage
Granulocyte-Macrophage Colony-Stimulating Factor - blood
Humans
Male
Medical sciences
Microbiology
Middle Aged
Predictive Value of Tests
Prospective Studies
Statistics, Nonparametric
Systemic inflammatory response syndrome
Systemic Inflammatory Response Syndrome - blood
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives. Granulocyte-macrophage colony stimulating factor (GM-CSF) is a key regulator cytokine that modulates the proliferation and maturation of polymorphonuclear and mononuclear progenitors. This study was designed to investigate and clarify the role of GM-CSF in 52 critically ill patients with systemic inflammatory response syndrome (SIRS). Methods. Serum levels of GM-CSF were detected by an immunoenzyme assay. Results. Our results clearly show that the serum concentrations of GM-CSF were significantly elevated in patients with infectious and noninfectious SIRS (33.2±45.7 pg/ml, controls: 17.2±9.8 pg/ml; p=0.0303). In addition, GM-CSF levels significantly decreased in patients with SIRS, particularly in patients with infectious SIRS, 5 and 7 days later. There was a clear tendency toward higher levels of GM-CSF in patients with poor, as compared with those having a good outcome of the disease. Conclusion. These results show that GM-CSF may play an important role in patients with infectious and noninfectious SIRS, and that GM-CSF levels progressively and significantly decrease in patients with infectious SIRS.
ISSN:0163-4453
1532-2742
DOI:10.1016/S0163-4453(03)00065-3